Amivantamab

埃万妥单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameAmivantamab
Drug Alias NameAmi-LC-MDAmivantamab admixed with rHuPH20Amivantamab-vmjwBispecific EGFR-cMet antibodyEGFR-MET bispecific antibody +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsEpidermal growth factor receptor erbB1 antagonists
TargetsHepatocyte growth factor receptorEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms +[12] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/21
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenmab A/SJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen-Cilag International NvJanssen Pharmaceutica NV +[15] 
Inactive CompaniesNational Cancer Institute
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms +[10] 
Inactive IndicationsCarcinoma, HepatocellularNeoplasms

Other Information

ATC CodeL01FX18
Related LinksDrugBankKEGG